Related Experiment Video

Updated: May 29, 2026

A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells
10:13

A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells

Published on: July 3, 2013

Canadian Expert Group consensus recommendations: KRAS testing in colorectal cancer

F Aubin1, S Gill, R Burkes

  • 1Centre Hospitalier de l'Université de Montréal, Montreal, QC.

Current Oncology (Toronto, Ont.)
|August 30, 2011
PubMed

Insights

KRAS testing is crucial for metastatic colorectal cancer patients treated with anti-EGFR antibodies. These guidelines standardize KRAS testing across Canada to ensure optimal patient care and access to this vital biomarker test.

Area of Science:

  • Oncology
  • Molecular Diagnostics

Background:

  • Anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibodies improve survival in metastatic colorectal cancer (mCRC).
  • Patients with KRAS mutations (codon 12 or 13) do not benefit from anti-EGFR therapies.
  • Standardized KRAS testing is essential for effective mCRC management.

Purpose of the Study:

  • To develop Canadian consensus recommendations for KRAS mutation testing in mCRC.
  • To standardize KRAS testing practices nationwide.
  • To align testing access with clinical demand.

Main Methods:

  • A Canadian consensus meeting was held in Montreal in April 2010.
  • Recommendations were developed using the best available evidence and expert opinion.
  • Guidelines cover indications, timing, sample requirements, reporting, and turnaround times for KRAS testing.

Main Results:

  • Established consensus recommendations for KRAS testing in mCRC.
  • Provided a framework for standardizing KRAS testing across Canada.
  • Addressed practical aspects of testing to improve accessibility and efficiency.

Conclusions:

  • Standardized KRAS testing is vital for guiding anti-EGFR therapy in mCRC.
  • These guidelines aim to optimize patient management and resource allocation for KRAS testing in Canada.
Keywords:
BRAF mutations testingKRAS mutations testinganti-egfr therapycetuximabconsensus recommendationsguidelinesmetastatic colorectal cancerpanitumumab

More Related Videos

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

Related Concept Videos

The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Serum Laboratory Studies, Stool Test, Breath Test01:30

Serum Laboratory Studies, Stool Test, Breath Test

Gastrointestinal (GI) diagnostic studies are pivotal in confirming, ruling out, diagnosing, or staging various diseases, including cancers. Following diagnosis, allocating time for discussions with the patient and providing informational resources is crucial. Diagnostic assessments of the GI tract often occur in outpatient settings like endoscopy suites or GI labs. Preparation for these tests may include dietary restrictions, fasting, liquid bowel preparations, laxatives, enemas, and the...